The company's proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce symptoms of bladder and bowel dysfunction. Axonics sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally.
Cyborg Score Rationale
Axonics operates in a specialized medical device market with FDA approval and established commercial distribution. The company has secured multiple capital raises and regulatory approvals, demonstrating investor confidence and product validation.
Top Insights
FDA-approved proprietary rechargeable SNM technology with multiple generations of product innovation
International expansion strategy across US, UK, Germany, Netherlands, and Nordic markets
Dual-product strategy combining SNM devices with urethral bulking agents for incontinence treatment
Significant capital raises through public offerings demonstrate strong investor backing and growth runway
Named Competitors
InterStim — Sacral neuromodulation system
Neurotech Devices — Neuromodulation portfolio
Recent Developments
(February 2021) FDA approval for third-generation implantable neurostimulator
(April 2020) FDA approval for second-generation rechargeable INS with extended recharge interval
(November 2019) U.S. commercial launch of r-SNM System
Open the full interactive Axonics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.